Track record · closed signal

Vericel Corporation (VCEL) — closed signal from January 13, 2026

Partial Published before the outcome was known, scored automatically when the window closed on April 13, 2026.

Predicted vs. what happened

VCEL price · publication thesis → realized outcomesplit-adjusted

$36.00 – $39.50Entry zone — fair-value band

$37.96Published — price the day we called it

$47.07Target — the price the thesis aimed for

$39.48Peak — highest point inside the window, not a realized return

$33.70Window close — end-of-window price, context only

What happened

Partial

Reached 17% of the predicted growth at its peak, without hitting the target.

Peak price

$39.48

peak on January 23, 2026 — not a realized return

Peak gain

+4%

peak, from the publication price

Window close

$33.70

end-of-window price, context only

Days to target

—

Window

January 13, 2026 – April 13, 2026

The thesis — published January 13, 2026

Predicted growth

+24%

over the measurement window

Target price

$47.07

the price the thesis aimed for

Entry zone

$36.00 – $39.50

the fair-value band we waited for

Price at publication

$37.96

published January 13, 2026

Confidence

77%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Shares fell recently and may bounce in the next 0-3 months because the company will present at a major healthcare conference this week. That presentation often brings attention and news that can lift the stock. Analysts also point to improving profits and steady sales guidance. Start small, add only if the price shows signs of strengthening, and keep positions small in case the event disappoints.

Primary drivers

Company presentation at a well-known healthcare conference can draw new attention
Recent big selloff means a rebound is more likely if sentiment improves
Better profit trends can make growth-focused investors interested
Smaller healthcare stocks often move quickly when coverage returns

How it played out

VCEL: short-term rebound missed the target

Lyra published VCEL at $37.96 on January 13, with an expected gain of 24%. The thesis pointed to a company presentation at a well-known healthcare conference, a recent big selloff, better profit trends, steady sales guidance, and the chance that coverage could return to smaller healthcare stocks.

Inside the January 13 to April 13 window, VCEL rose as high as $39.48 on January 23, a 4% peak gain. It stayed below the $47.07 target and never reached it. The stock ended at $33.70. The thesis expected a short-term rebound, but the window closed with the price lower than publication. It missed.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All VCEL signals